Eupraxia Pharmaceuticals (EPRX) Stock Chart & Stock Price History $3.18 -0.30 (-8.62%) (As of 10:55 AM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Eupraxia Pharmaceuticals Stock Price Performance5 Day Performance+27.20%1 Month Performance+20.00%3 Month Performance+21.37%6 Month Performance+8.16% Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter Email Address Ad TradingTips10 EV Stocks to Buy Right NowEV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. EPRX Stock Chart for Tuesday, November, 5, 2024 EPRX Chart by TradingView Eupraxia Pharmaceuticals Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/04/2024$3.10$3.48+12.26%$3.49$2.9551,007 shs$94.93 million11/01/2024$2.50$3.07+22.80%$3.79$2.50210,517 shs$83.75 million10/31/2024$2.50$2.50$2.50$2.472,149 shs$68.21 million10/30/2024$2.43$2.50+2.88%$2.50$2.472,149 shs$68.21 million10/29/2024$2.55$2.43-4.71%$2.80$2.4110,214 shs$66.30 million10/28/2024$2.58$2.55-1.16%$2.56$2.453,988 shs$69.56 million Get the Latest News and Ratings for EPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/25/2024$2.49$2.58+3.61%$2.58$2.334,566 shs$70.39 million10/24/2024$2.50$2.49-0.40%$2.49$2.37788 shs$67.93 million10/23/2024$2.41$2.50+3.73%$2.50$2.451,730 shs$68.21 million10/22/2024$2.43$2.41-0.82%$2.51$2.316,828 shs$65.75 million10/21/2024$2.51$2.43-3.19%$2.49$2.3714,525 shs$66.30 million10/18/2024$2.45$2.51+2.45%$2.55$2.455,148 shs$68.48 million10/17/2024$2.48$2.45-1.21%$2.63$2.452,161 shs$66.84 million10/16/2024$2.43$2.48+2.06%$2.81$2.3825,550 shs$67.66 million10/15/2024$2.36$2.43+2.97%$2.43$2.233,497 shs$66.30 million10/14/2024$2.40$2.36-1.67%$2.54$2.204,203 shs$64.39 million10/11/2024$2.32$2.40+3.45%$2.60$2.275,950 shs$65.47 million10/10/2024$2.32$2.32$2.39$2.221,648 shs$63.29 million10/09/2024$2.30$2.32+0.87%$2.63$2.2421,596 shs$63.29 million10/08/2024$2.49$2.30-7.63%$2.60$2.3023,531 shs$62.75 million10/07/2024$2.65$2.49-6.04%$2.64$2.496,674 shs$67.93 million10/04/2024$2.59$2.65+2.32%$2.75$2.616,680 shs$72.30 million10/03/2024$2.64$2.59-1.89%$2.74$2.426,404 shs$70.66 million10/02/2024$2.64$2.64$2.64$2.64415 shs$72.02 million10/01/2024$2.63$2.64+0.38%$2.64$2.64415 shs$72.02 million09/30/2024$2.63$2.63+0.00%$2.68$2.422,220 shs$71.75 million09/27/2024$2.63$2.63$2.63$2.50583 shs$71.75 million09/26/2024$2.56$2.63+2.73%$2.69$2.631,510 shs$71.75 million09/25/2024$2.73$2.56-6.23%$2.84$2.569,706 shs$69.84 million09/24/2024$2.81$2.73-2.85%$2.74$2.73315 shs$74.48 million09/23/2024$2.87$2.81-2.23%$2.93$2.81538 shs$76.66 million09/20/2024$2.80$2.87+2.50%$2.94$2.825,048 shs$78.30 million09/19/2024$2.83$2.80-1.06%$2.80$2.643,414 shs$76.39 million09/18/2024$2.70$2.83+4.81%$2.83$2.653,101 shs$77.21 million09/17/2024$2.56$2.70+5.47%$2.72$2.555,850 shs$73.66 million09/16/2024$2.58$2.56-0.78%$2.85$2.4113,304 shs$69.84 million09/13/2024$2.42$2.58+6.61%$2.58$2.454,990 shs$70.38 million09/12/2024$2.66$2.42-9.02%$2.62$2.421,091 shs$66.02 million09/11/2024$2.61$2.66+1.92%$2.77$2.461,943 shs$72.57 million09/10/2024$2.49$2.61+4.82%$2.64$2.61783 shs$71.21 millionThe Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you.09/09/2024$2.54$2.49-1.97%$2.63$2.455,932 shs$67.93 million09/06/2024$2.47$2.54+2.83%$2.60$2.446,444 shs$69.30 million09/05/2024$2.45$2.47+0.82%$2.51$2.452,238 shs$67.39 million09/04/2024$2.60$2.45-5.77%$2.73$2.453,513 shs$66.84 million09/03/2024$2.55$2.60+1.96%$2.75$2.504,708 shs$70.93 million09/02/2024$2.55$2.55$2.77$2.4720,100 shs$69.56 million08/30/2024$2.50$2.55+2.00%$2.77$2.4720,113 shs$69.57 million08/29/2024$2.62$2.50-4.58%$2.70$2.508,030 shs$68.21 million08/28/2024$2.75$2.62-4.73%$2.75$2.547,123 shs$71.48 million08/27/2024$2.62$2.75+4.96%$2.75$2.597,071 shs$75.03 million08/26/2024$2.67$2.62-1.87%$2.62$2.62391 shs$71.48 million08/23/2024$2.60$2.67+2.69%$2.69$2.67275 shs$72.84 million08/22/2024$2.67$2.60-2.62%$2.71$2.60564 shs$70.93 million08/21/2024$2.71$2.67-1.48%$2.81$2.67517 shs$72.84 million08/20/2024$2.75$2.71-1.45%$2.80$2.669,633 shs$73.93 million08/19/2024$2.55$2.75+7.84%$2.75$2.52614 shs$75.03 million08/16/2024$2.60$2.55-1.92%$2.73$2.555,612 shs$69.57 million08/15/2024$2.61$2.60-0.38%$2.70$2.474,717 shs$70.93 million08/14/2024$2.49$2.61+4.82%$2.78$2.61451 shs$71.21 million08/13/2024$2.72$2.49-8.46%$2.59$2.491,608 shs$67.93 million08/12/2024$2.68$2.72+1.49%$2.84$2.721,481 shs$74.21 million08/09/2024$2.52$2.68+6.35%$2.74$2.591,515 shs$73.12 million08/08/2024$2.40$2.52+5.00%$2.53$2.433,451 shs$68.75 million08/07/2024$2.50$2.40-4.00%$2.69$2.3925,551 shs$65.48 million08/06/2024$2.62$2.50-4.58%$2.76$2.505,900 shs$68.21 million08/05/2024$2.57$2.62+1.95%$2.62$2.57155 shs$71.48 million Related Companies ProQR Therapeutics Stock Chart Heron Therapeutics Stock Chart Immutep Stock Chart Genfit Stock Chart ChromaDex Stock Chart Editas Medicine Stock Chart TScan Therapeutics Stock Chart Cadrenal Therapeutics Stock Chart 2seventy bio Stock Chart Enanta Pharmaceuticals Stock Chart Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:EPRX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts